1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Vital Signs The Analyst%s Perspective - July 2015 Issue 

Vital Signs The Analyst%s Perspective - July 2015 Issue 

  • August 2015
  • -
  • Frost & Sullivan
  • -
  • 6 pages

This issue of Vital Signs, released in August 2015, discusses The Real Fight Against Cancer: The Struggle to make Drugs Affordable, OPKO Health's acquisition of Bio-Reference Laboratories, Health Insurance Company Mergers – How will Consumers Fare?, and Illumina's acquisition of GenoLogics.

Table Of Contents

Vital Signs The Analyst%s Perspective - July 2015 Issue 
LIFE SCIENCES

The Real Fight Against Cancer: The Struggle to Make Drugs Affordable 2
OPKO Health Acquires Bio-Reference Laboratories 2
Health Insurance Company Mergers - How will Consumers Fare? 4
Illumina, Inc Acquires GenoLogics Life Sciences Software for LIMS Capabilities 5

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Cancer Industry in the UK

  • February 2017
    66 pages
  • Cancer  

  • United Kingdom  

View report >

Cancer Statistics in Australia - Forecast

  • February 2017
    4 pages
  • Cancer  

    Ovarian Cancer  

  • Australia  

    Oceania  

View report >

Cancer Statistics in the UK

  • February 2017
    11 pages
  • Cancer  

  • United Kingdom  

    Australia  

    Denmark  

View report >

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.